(PDF) Intratumoral Epiregulin Is a Marker of Advanced

Intratumoral Epiregulin Is a Marker of Advanced Disease in Non-Small Cell Lung Cancer Patients and Confers Invasive Properties on EGFR-Mutant Cells

Cancer Prevention Research - United States

doi 10.1158/1940-6207.capr-08-0014

Full Text

Abstract

Available in full text

Categories

Cancer Research

Date

May 18, 2008

Authors

Publisher

American Association for Cancer Research (AACR)

Related search

P2.01-79 Neurological Death Is Common in Patients With EGFR Mutant Non-Small Cell Lung Cancer

Journal of Thoracic Oncology

Respiratory Medicine

English

P2.01-117 Concurrent Gene Alterations in Treatment-Naïve EGFR-Mutant Advanced Non-Small Cell Lung Cancer

Journal of Thoracic Oncology

Respiratory Medicine

English

P3.13-15 First-Line Afatinib Dose Initiation and Adjustment in Patients With EGFR Mutant Advanced Non-Small Cell Lung Cancer

Journal of Thoracic Oncology

Respiratory Medicine

English

P3.01-95 EGFR Genotype as a Predictor of Survival in EGFR Mutant Non-Small Cell Lung Cancer

Journal of Thoracic Oncology

Respiratory Medicine

English

Spatiotemporal T790M Heterogeneity in a Patient With EGFR-Mutant Non–Small-Cell Lung Cancer

Journal of Thoracic Oncology

Respiratory Medicine

English

P3.15-21 Real-World Experience of First-Line Afatinib Treatment in Patients With EGFR Mutant Advanced Non-Small Cell Lung Cancer

Journal of Thoracic Oncology

Respiratory Medicine

English

P1.01-47 Phase I/Ii Trial of Dasatinib and Osimertinib in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology

Respiratory Medicine

English

Advanced Non-Small Cell Lung Cancer in Elderly Patients

Respiratory Medicine

English

Role of FBXW7 in the Quiescence of Gefitinib-Resistant Lung Cancer Stem Cells in EGFR-mutant Non-Small Cell Lung Cancer

Bosnian Journal of Basic Medical Sciences

English